Expert opinion on NSCLC small specimen biomarker testing - Part 2: Analysis, reporting, and quality assessment.
The diagnostic work-up for non-small cell lung cancer (NSCLC) requires biomarker testing to guide therapy choices. This article is the second of a two-part series. In Part 1, we summarised evidence-based recommendations for obtaining and processing small specimen samples (i.e. pre-analytical steps)...
| Publicado en: | Virchows Archiv: European Journal of Pathology Vol. 481; no. 3; pp. 351 - 367 |
|---|---|
| Autores principales: | , , , , , , , , , , , |
| Formato: | research Journal Article |
| Publicado: |
Springer Nature
Sep2022
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=159197688&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 159197688 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 09456317 O1Z jtl: Virchows Archiv: European Journal of Pathology issn: 09456317 maglogo: N pubinfo: dt: Sep2022 vid: 481 iid: 3 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 159197688 159197688 NLM35857103 159197688 10.1007/s00428-022-03344-1 NLM35857103 159197688 ppf: 351 ppct: 16 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Expert opinion on NSCLC small specimen biomarker testing - Part 2: Analysis, reporting, and quality assessment. aug: au: Penault-Llorca, Frédérique Kerr, Keith M. Garrido, Pilar Thunnissen, Erik Dequeker, Elisabeth Normanno, Nicola Patton, Simon J. Fairley, Jenni Kapp, Joshua de Ridder, Daniëlle Ryška, Aleš Moch, Holger affil: University Clermont Auvergne, INSERM U1240, Centre Jean Perrin, Clermont-Ferrand, France sug: subj: Carcinoma, Non-Small-Cell Lung Pathology Lung Neoplasms Diagnosis Carcinoma, Non-Small-Cell Lung Carcinoma, Non-Small-Cell Lung Diagnosis Lung Neoplasms Lung Neoplasms Drug Therapy Mutation Human Witness, Legal Sequence Analysis Methods Scales Ferrans and Powers Quality of Life Index ab: The diagnostic work-up for non-small cell lung cancer (NSCLC) requires biomarker testing to guide therapy choices. This article is the second of a two-part series. In Part 1, we summarised evidence-based recommendations for obtaining and processing small specimen samples (i.e. pre-analytical steps) from patients with advanced NSCLC. Here, in Part 2, we summarise evidence-based recommendations relating to analytical steps of biomarker testing (and associated reporting and quality assessment) of small specimen samples in NSCLC. As the number of biomarkers for actionable (genetic) targets and approved targeted therapies continues to increase, simultaneous testing of multiple actionable oncogenic drivers using next-generation sequencing (NGS) becomes imperative, as set forth in European Society for Medical Oncology guidelines. This is particularly relevant in advanced NSCLC, where tissue specimens are typically limited and NGS may help avoid tissue exhaustion compared with sequential biomarker testing. Despite guideline recommendations, significant discrepancies in access to NGS persist across Europe, primarily due to reimbursement constraints. The use of increasingly complex testing methods also has implications for the reporting of results. Molecular testing reports should include clinical interpretation with additional commentary on sample adequacy as appropriate. Molecular tumour boards are recommended to facilitate the interpretation of complex genetic information arising from NGS, and to collaboratively determine the optimal treatment for patients with NSCLC. Finally, whichever testing modality is employed, it is essential that adequate internal and external validation and quality control measures are implemented. pubtype: Academic Journal doctype: research Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|